Earnings Call · Q2 FY2024·2024-08-08

Q2 24EPS +25.63%·Rev n/aQ1 24EPS +13.16%·Rev n/aQ4 23EPS -2.27%·Rev n/aQ3 23EPS +19.27%·Rev n/a⚠ consensus missing

GILEAD SCIENCES, INC. GILD

Jacquie Ross — Vice President, Investor Relations

Daniel O'Day — Chairman and Chief Executive Officer

Johanna Mercier — Chief Commercial Officer

Merdad Parsey — Chief Medical Officer

Andrew Dickinson — Chief Financial Officer

−2.6%1d on move date−3.0% vs SPY3d−2.1%5d−1.7%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more GILD calls or request research access.

More GILD calls Browse calls Request research access